Shares of METIS TECHBIO-P (07666) jumped more than 16% in early trading, leading gains among AI drug development concept stocks. As of the latest update, the stock was up 11.43% at HK$15.40, with turnover reaching HK$155.4 million.

The Shanghai Stock Exchange issued a notice after market close on September 4, confirming that METIS TECHBIO-P has been officially added to the Stock Connect eligible securities list, with the adjustment taking effect on Monday, September 7. This development enables mainland investors to buy and sell METIS TECHBIO-P directly through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect channels, formally unlocking southbound capital flows.

The board believes that this inclusion will help broaden the shareholder base, attract long-term institutional investors, and enhance the liquidity of share trading. Notably, in the first half of the year, the commercialization results of METIS TECHBIO-P's NanoForge platform entered a period of concentrated release. During the period, revenue exceeded RMB 154 million, surpassing 47% of the total revenue for the entire previous year; adjusted net losses narrowed significantly by 56.4% to RMB 51 million, while R&D expenditures increased by 48.1% year-on-year to RMB 172 million.

During the reporting period, the company's platform capabilities expanded from designing drug delivery systems to systematic design of proteins, nucleic acids, delivery systems, and cellular states; the AI-driven nano delivery platform NanoForge accelerated its commercialization process in the field of AI for Science (AI4S).